EWTX - Edgewise Therapeutics

-

$undefined

N/A

(N/A)

Edgewise Therapeutics NASDAQ:EWTX Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases.

Location: | Website: edgewisetx.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

2.177B

Cash

492.5M

Avg Qtr Burn

-27.23M

Short % of Float

10.56%

Insider Ownership

0.47%

Institutional Own.

-

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Sevasemten (EDG-5506) Details
Becker Muscular Dystrophy

Phase 2

Data readout

EDG-7500 Details
Heart disease, Hypertrophic cardiomyopathies

Phase 2

Data readout

Sevasemten (EDG-5506) Details
Rare diseases, Duchenne muscular dystrophy

Big Mover™

Phase 2

Data readout

Sevasemten (EDG-5506) Details
Becker Muscular Dystrophy

Big Mover™

Susp. Mover™

Phase 2

Data readout

Sevasemten (EDG-5506) Details
Duchenne muscular dystrophy, Rare diseases

Phase 2

Update

Sevasemten (EDG-5506) Details
Rare diseases, Limb-Girdle Muscular Dystrophy, McArdle disease

Phase 2

Update

Sevasemten (EDG-5506) Details
Becker Muscular Dystrophy

Phase 1b

Update